Press Releases

Year

Dec 15, 2020

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was

Dec 09, 2020

Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the launch of Galactosemia

Dec 09, 2020

Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study

Nov 12, 2020

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics) On track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half of 2021 Continued

Nov 09, 2020

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) NEW YORK , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug

Oct 21, 2020

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting

NEW YORK , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two

Sep 24, 2020

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

NEW YORK , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the U.S.

Sep 17, 2020

Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of Diabetes

NEW YORK , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two

Sep 02, 2020

Applied Therapeutics to Present at Citi and Baird Investor Conferences

NEW YORK , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at

Aug 11, 2020

Applied Therapeutics Reports Second Quarter 2020 Financial Results

NEW YORK , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28

Desktop - About Us

Desktop - Pipeline

Desktop - Patients & Caregivers

Desktop - Investor Menu

Mobile Header Links

Footer Disclaimer Links

Social Links

Social Links

Footer Disclaimer Links